Evidence map›Paper›PMID 26421711›Full record

ArticleOncotarget2015

Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: Understanding WNT/FGF-driven anabolic signaling.

Rebecca Lamb, Gloria Bonuccelli, Béla Ozsvári, Maria Peiris-Pagès, Marco Fiorillo, Duncan L Smith, Generoso Bevilacqua, Chiara Maria Mazzanti, Liam A McDonnell, Antonio Giuseppe Naccarato and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 2 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 2 syntheses or guidelines pooled it, 132 citations in OpenAlex.

  1. Pooled it
  2. PGC1α-Mediated Metabolic Reprogramming Drives the Stemness of Pancreatic Precursor Lesions.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Pooled it
  3. Article
  4. The metabolic profiles of cancer stem cells.Stem cell research & therapy · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. APOE4 impairs autophagy and Aβ clearance by microglial cells.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Rebecca LambThe Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK.
Gloria BonuccelliThe Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK.
Béla OzsváriThe Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK.
Maria Peiris-PagèsThe Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK.
Marco FiorilloThe Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK.
Duncan L SmithThe Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK.
Generoso BevilacquaFPS - The Pisa Science Foundation, Pisa, Italy.
Chiara Maria MazzantiFPS - The Pisa Science Foundation, Pisa, Italy.
Liam A McDonnellFPS - The Pisa Science Foundation, Pisa, Italy.
Antonio Giuseppe NaccaratoDepartment of Pathology, Pisa University Hospital, Pisa, Italy.
Maybo ChiuThe Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK.
Luke WynneThe Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK.
Ubaldo E Martinez-OutschoornThe Sidney Kimmel Cancer Center, Philadelphia, PA, USA.
Federica SotgiaThe Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK.
Michael P LisantiThe Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK.
Breast Cancer Now · GBFondazione Pisa · ITUniversity of Manchester · GBCancer Research UK Manchester Institute · GBSidney Kimmel Cancer Center · USUniversity of Calabria · IT

Funding

Metabolic mechanisms of antiestrogen resistance in breast cancerK08CA175193 · NCI · THOMAS JEFFERSON UNIVERSITY · PI MARTINEZ OUTSCHOORN, UBALDO · 2013 to 2017
$831k
NCI NIH HHS K08 CA175193NCI NIH HHS K08-CA175193-01A1
6 · The paper itself

Abstract

Here, we developed an isogenic cell model of "stemness" to facilitate protein biomarker discovery in breast cancer. For this purpose, we used knowledge gained previously from the study of the mouse mammary tumor virus (MMTV). MMTV initiates mammary tumorigenesis in mice by promoter insertion adjacent to two main integration sites, namely Int-1 (Wnt1) and Int-2 (Fgf3), which ultimately activates Wnt/β-catenin signaling, driving the propagation of mammary cancer stem cells (CSCs). Thus, to develop a humanized model of MMTV signaling, we over-expressed WNT1 and FGF3 in MCF7 cells, an ER(+) human breast cancer cell line. We then validated that MCF7 cells over-expressing both WNT1 and FGF3 show a 3.5-fold increase in mammosphere formation, and that conditioned media from these cells is also sufficient to promote stem cell activity in untransfected parental MCF7 and T47D cells, as WNT1 and FGF3 are secreted factors. Proteomic analysis of this model system revealed the induction of i) EMT markers, ii) mitochondrial proteins, iii) glycolytic enzymes and iv) protein synthesis machinery, consistent with an anabolic CSC phenotype. MitoTracker staining validated the expected WNT1/FGF3-induced increase in mitochondrial mass and activity, which presumably reflects increased mitochondrial biogenesis. Importantly, many of the proteins that were up-regulated by WNT/FGF-signaling in MCF7 cells, were also transcriptionally over-expressed in human breast cancer cells in vivo, based on the bioinformatic analysis of public gene expression datasets of laser-captured patient samples. As such, this isogenic cell model should accelerate the discovery of new biomarkers to predict clinical outcome in breast cancer, facilitating the development of personalized medicine.Finally, we used mitochondrial mass as a surrogate marker for increased mitochondrial biogenesis in untransfected MCF7 cells. As predicted, metabolic fractionation of parental MCF7 cells, via MitoTracker staining, indicated that high mitochondrial mass is a new metabolic biomarker for the enrichment of anabolic CSCs, as functionally assessed by mammosphere-forming activity. This observation has broad implications for understanding the role of mitochondrial biogenesis in the propagation of stem-like cancer cells. Technically, this general metabolic approach could be applied to any cancer type, to identify and target the mitochondrial-rich CSC population.The implications of our work for understanding the role of mitochondrial metabolism in viral oncogenesis driven by random promoter insertions are also discussed, in the context of MMTV and ALV infections.

Indexed as

Biomarkers, TumorBreast NeoplasmsCulture Media, ConditionedFemaleFibroblast Growth Factor 3HumansMammary Tumor Virus, MouseMCF-7 CellsMembrane Potential, MitochondrialMitochondriaModels, BiologicalNeoplastic Stem CellsSpheroids, CellularTumor Cells, CulturedWnt1 ProteinWnt Signaling PathwayBiomarkers, TumorCulture Media, ConditionedFGF3 protein, humanFibroblast Growth Factor 3Wnt1 ProteinWNT1 protein, humanFGFmitochondriaMitoTrackerMMTVWNT

Identifiers

PMID26421711
PMCPMC4741544
OpenAlexW2153597782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.